To date, BRCA1/2 has been very well studied in breast cancer and gynecological oncology, and BRCA2 mutation carriers have been described to be significantly associated with an elevated risk for prostate cancer, colorectal cancer and urothelial carcinoma (22–25). Here, BRCA1 is linked to breast carcinoma.